Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Oncogenic and teratogenic effects of p53Y217C, a mouse model of the human hotspot mutant p53Y220C

View through CrossRef
Abstract Missense “hotspot” mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether they may gain additional functions promoting tumorigenesis remains controversial. Here we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C. DNA damage responses were lost in p53Y217C/Y217C cells. Surprisingly, intercrosses from p53+/Y217C heterozygotes yielded only one p53Y217C/Y217C female for nineteen p53Y217C/Y217C males at weaning, a skewed distribution explained by the high frequency of p53Y217C/Y217C female embryos with exencephaly and the death of most p53Y217C/Y217C female neonates. Furthermore, parturition was impaired in pregnant p53Y217C/Y217C females. Finally, p53Y217C/Y217C males died earlier than p53-/- males, with more aggressive thymic lymphomas. Together, these data indicate that the p53Y217C mutation not only abrogates wildtype p53 functions, but also exerts additional effects promoting oncogenesis in males and teratogenesis or dystocia in females.
Title: Oncogenic and teratogenic effects of p53Y217C, a mouse model of the human hotspot mutant p53Y220C
Description:
Abstract Missense “hotspot” mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers.
Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether they may gain additional functions promoting tumorigenesis remains controversial.
Here we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C.
DNA damage responses were lost in p53Y217C/Y217C cells.
Surprisingly, intercrosses from p53+/Y217C heterozygotes yielded only one p53Y217C/Y217C female for nineteen p53Y217C/Y217C males at weaning, a skewed distribution explained by the high frequency of p53Y217C/Y217C female embryos with exencephaly and the death of most p53Y217C/Y217C female neonates.
Furthermore, parturition was impaired in pregnant p53Y217C/Y217C females.
Finally, p53Y217C/Y217C males died earlier than p53-/- males, with more aggressive thymic lymphomas.
Together, these data indicate that the p53Y217C mutation not only abrogates wildtype p53 functions, but also exerts additional effects promoting oncogenesis in males and teratogenesis or dystocia in females.

Related Results

p53Y220C-BET-bifunctionals (tPRIMEs) drive p53Y220C-mutant cancer cells into apoptosis
p53Y220C-BET-bifunctionals (tPRIMEs) drive p53Y220C-mutant cancer cells into apoptosis
Abstract The transcription factor and tumor suppressor p53 is one of the most frequently mutated genes in cancer and has been difficult to target...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C
Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C
Abstract Missense “hotspot” mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppre...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...

Back to Top